Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lescarden, a biotechnology company, has entered into a distribution agreement with Cranage Healthcare, a provider of critical care products, to market Lescarden's proprietary Catrix wound dressing in the UK and Ireland.
Subscribe to our email newsletter
Lescarden’s Catrix Wound Dressing utilizes bovine cartilage that has been refined into a fine, white powder. It has been shown in extensive clinical testing to be an effective aid in the healing of wounds that are resistant to the healing process. The product has been approved by the FDA for the management of first and second degree burns as well as decubitus ulcers, venous stasis and diabetic ulcers and post-radiation dermatitis.
The Catrix Wound Dressing is currently being distributed in Spain by Smith and Nephew. Regulatory marketing approvals and product reimbursement arrangements are being secured, and it is anticipated that product launch will commence in the first quarter of 2009.
William Luther, president of Lescarden, said: “We are pleased with this new distribution agreement, which should enable us to make a significant penetration, for the first time, into one of the most important European markets for our products.”